Gene therapy company GNVC will acquire cell transplantation company DCRN in a stock transaction valued at $40.4 million. GNVC will gain DCRN's cash and equivalents, which totaled $44.9 million as of Dec. 31, 2002. The...
Gene therapy company GNVC will acquire cell transplantation company DCRN in a stock transaction valued at $40.4 million. GNVC will gain DCRN's cash and equivalents, which totaled $44.9 million as of Dec. 31, 2002. The...